MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes

Researchers followed up a multiple-ascending dose (MAD) investigation with a Phase IIa trial to evaluate MEDI0382 as a pathway for helping type 2 diabetics lose weight and improve glycemic control. The study population, culled from 11 German sites, included adult patients with controlled disease and a body mass index of 27–40 kg/m2.

Researchers followed up a multiple-ascending dose (MAD) investigation with a Phase IIa trial to evaluate MEDI0382 as a pathway for helping type 2 diabetics lose weight and improve glycemic control. The study population, culled from 11 German sites, included adult patients with controlled disease and a body mass index of 27–40 kg/m2. Based on random assignment, 25 participants received once-daily injections of MEDI0382 and 26 received placebo for a period of 41 days. Results tied the study drug to a significant drop in body weight from baseline compared with placebo. In addition, glucose area under the curve 0–4 hours after a mixed-meal tolerance test declined markedly from baseline with MEDI0382 than without. The incidence of treatment-related adverse events was similar between the two treatment arms, meanwhile, although gastrointestinal disorders and decreased appetite were more common among the MEDI0382 patients. The team of German, U.S., and U.K. investigators concluded that MEDI0382 promises to produce clinically meaningful reductions in blood glucose and body weight in heavy patients with type 2 diabetes—a goal that to date has been elusive.